Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Merus N.V. MRUS shares have jumped 29.9% over the past three months. The uptrend was fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab ...

The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and ...

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and ...

StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its stock jump 45% after unveiling preliminary data from the first patient ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

in combination with Merck’s Keytruda (pembrolizumab) for PDL1+ first-line (1L) HNSCC. Bicara presented Phase I/Ib data for ...